Company: SMNR
Filing Date: 2025-08-08
Form Type: S-4/A
Source: 0001193125-25-177097
Chunk: 615

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-08
Form: S-4/A
Chunk 615
---
 15,000 |

| Equity Compensation   |     | Number |         |
| Initial Stock Options |     |        | 250,000 |
| Annual Stock Options  |     |        | 100,000 |

All annual cash compensation amounts for New Semnur’s non-employee directorsare expected to be payable in equal quarterly installments in arrears, following the end of each quarter in which the service occurred, pro-rated forany partial months of service. The equity compensation to be paid to New Semnur’s non-employee directorswill vest monthly over a period of 48 months from the date of grant with respect to the initial stock option grants and over a period of 12 months from the date of grant with respect to the annual stock option grants, in each case, subject to continued service through each vesting date. Additionally, New Semnur will reimburse each outside director for reasonable travel expenses related to such director’s attendance at meetings of the New Semnur Board and any committees thereof. New Semnur’s employee directors will not receive additional compensation for their service as a director. 374

DIRECTORS AND EXECUTIVE OFFICERS OF NEW SEMNUR AFTER THE BUSINESS COMBINATION The following sets forth certain information, as of the date of this proxy statement/prospectus concerning the persons who are expected to serve as directors and executive officers of New Semnur following the consummation of the Business Combination. Executive Officers and Directors after the Business Combination Upon the consummation of the Business Combination, the business and affairs of New Semnur will be managed by or under the direction of the New Semnur Board. The following table sets forth the name, age and position of each of the expected directors and executive officers of New Semnur following the consummation of the Business Combination as of December 31, 2024.

| Name                             |     | Age |     | Position(s)                                                  |
| Executive Officers:              |     |     |     |                                                              |
| Jaisim Shah                      |     |  65 |     | Chief Executive Officer, President and Director              |
| Henry Ji, Ph.D.                  |     |  61 |     | Executive Chairperson and Director                           |
| Stephen Ma                       |     |  53 |     | Chief Financial Officer, Senior Vice President and Secretary |
| Non-employee Directors:          |     |     |     |                                                              |
| Jay Chun, M.D., Ph.D.(1)         |